We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Loads-You are not NoLupus and you did not answer my question-several multiples is not a range. The IF stuff is obvious.
That's all.
Wildbunch - though I'm not Nolupus, I think I can safely answer your question. Obviously, IF a drug is eventually brought to market, IMM's share price will be several multiples of its current level. However, everything hinges on the word IF - and the current perceived likelihood of successful commercialistion - which is why the price remains around the 3p mark at the moment. Cash runway - at least beyond 2024 - remains a concern here.
I think we should see the buying starting today leading into the month of June, which could well be transformational for IMM
NoLupus-what do you glimpse as a realistic range of market caps for IMM if one of the 2 projected attempts at bringing the drug to market comes off in 3 to 4 years time?
That's all.
Still no RNS telling us that they have submitted their IND application along with Orphan drug application. I would have thought they would had a draft ready and waiting as they felt so confident about the FDA meeting. Why is everything so slow with them or are there further changes required by the FDA that Imm have not shared?
Closed @ 3.10p - 3.29p on the ask, although the full story is not been told on LSE
but I'm positive it will level back out in the Morning
then onward's and upwards hopefully''
IMO, with the stars aligning for IMM ATM, and MM seems happy to hold price around 3p anything can happen
we will see
..... struggling to stay above 3p.
Cauldstream7,
Prof Muller is your Sherlock Holmes ? Yes she invented the P140/ Lupuzor more than 20 years ago , and so far nothing on the market !!
Without giving away her personal details , she is over seventy so try and keep that in mind
I try not to engage much with him poker'' as i also know his game, only positive when he get his buying price
and IMO, he perhaps sold out 28th APRIL because after that date he started talking about
people that bought sub 2p will be taking some of the table, then his post started to slow down
when we got that surprise RNS, and ever since its been placing in most of his post
and lately seem to be getting desperate enough to follow other trolls to hammer hope placing
but may i remind them that we are fully funded to 2024 and if we was to get some more money
in the coffers it would be from a HNW investor who would want in at a premium to where we are now''
or it will be from our partner Avion who would want a bit more than the 3% they have already
before FDA approval
see what happen in the days ahead, as i suspect we will hold 3p and above quite well
right up to the next FDA meeting that is only days away''
Regards
Nolupus.
To judge the importance of a scientific discovery by the number of employees involved in the lab and behind-the-scenes work is daft. One Sherlock Holmes is worth a 1000 plods on the beat.
In any case, P140 was discovered around 10 years ago by Prof Sylvane Muller so what does that have to do with current employee numbers at CNRS?
Cauldstream7,
The CNRS he nearly 32 000 employees … How many do you think are working on the P140 ?
Put things into perspective -)
Lordloadsoflolly
posters and readers here are merely foot soldiers to our resident trader ....that he seeks to recruit to assist his trades ( which are far smaller in size than his ramping posts might suggest)
He has already more or less said he sold his trade when it reached 3.30p from his 2.6p buy....so his aim now is to recruit foot soldier sellers willing to sacrifice their shares , in order to assist in his next trade opportunity ...which he no doubt sees as the date for the next FCA meeting approaches
All a game but done so often that it has become extremely transparent rather than being opaque
Cant be anyone left who hasn't seen the method of the game
Lambo222 - phew, that's alright then. For a moment there, I thought you were scaremongering.
And now, back to the music.......
.... IN OUT, IN OUT, SHAKE IT ALL ABOUT
They could do with a new strategic investor ....rather than using the likes of Landstead etc .....and the precision, care and FDA advise they have taken over the preparations for the Lupuzor trial ......"might" bring one in
I would assume the placing will be at around 2.5p if it happens and only small hopefully
Nolupus:
My assessment of the relationship between CNRS and IMM is not overblown. I believe that it is not one of thousands of the same between CNRS and other companies. The agreement for the sharing of patents relating to P140 is of major importance and could have huge implications for the health of millions of sufferers from diseases of the immune system, as well as the earnings of IMM and CNRS through its licensing agreement with IMM for the P140 patents.
They will need cash here dont get caught out at 2p
Loads-agree with you. No way there will be a placing before next FDA meet. Lambo wants price down!
That's all.
Lambo222,
I don’t think that a placing is on the cards BEFORE the 10:06 at least , otherwise Tim would have to give the LClub more warrants/options ( if placing price below 5 p )
I dont want a placing at least not anytime soon!! I’m saying they have done one twice before last FDA decisions and if it does go badly they hve no cash and no ability to raise so they are stuck between a Rock and a hard place really, that’s why I’m saying I’d prefer them to take the risk and not place and just continue not taking a salary
Here we go again - lambo222 sewing seeds of doubt with his "I really do hope the bod don’t do a placing atm".
Knees bent, arms stretched, ra ra ra
I really do hope the bod don’t do a placing atm, the market is terrible for fundraising for pharma and biotech as seen by the FAB placing last week, no salary and tight financial controls are needed the last thing we need here is a placing after a good bit of positive news flow last few months with the price up 100% from 1.6p
Very strange trading day
Wow FAB placing at 85% discount!! Thank the lord for Lanstead funding lol
Cauldstream7,
You seem to have blown out of all proportions the relationship between IMM and the CNRS …
They are both co owners of the P140 patents whilst IMM has the commercial rights to advance the clinical trials / marketing etc
The CNRS is a major European research institute and the Imm connexion is only one of many thousands of programs in which they participate….